ANXA1 has also been observed to influence immune cells and the tumour microenvironment by enhancing regulatory T-cell function [20], enhancing the polarisation and activation of M2 tumour-associated macrophages [21], suppressing dendritic cell activation and impairing CD8+ T-cell anti-tumour immunity [22]. The gene discussed is CD8A; the disease is neoplasm.